Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.57 |
| ▸ | ACHE | P22303 | 7/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30099796 | 0.94 | EPHX1 (0.63) | EPHX1ACHEEPHX2 | |
| SCHEMBL26669250 | 0.91 | EPHX1 (0.59) | EPHX1ACHEEPHX2 | |
| SCHEMBL24438211 | 0.91 | EPHX1 (0.67) | EPHX1TSHREPHX2 | |
| SCHEMBL6287134 | 0.87 | EPHX1 (0.55) | EPHX1ACHEEPHX2 | |
| SCHEMBL18235597 | 0.87 | ACHE (0.56) | EPHX1ACHETSHREPHX2 | |
| SCHEMBL6289672 | 0.87 | ACHE (0.56) | EPHX1ACHETSHREPHX2 | |
| SCHEMBL6289675 | 0.87 | EPHX1 (0.55) | EPHX1ACHETSHREPHX2 | |
| SCHEMBL14984055 | 0.87 | EPHX1 (0.73) | EPHX1EPHX2 | |
| SCHEMBL11230123 | 0.86 | EPHX2 (0.56) | EPHX1TSHREPHX2 | |
| SCHEMBL6284981 | 0.86 | EPHX1 (0.53) | EPHX1ACHETSHREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9006281-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-9006281-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2015-04-14 | — | — | US | disclosed |